Saturday 17 October 2026
Export NIKI’s income statement to Excel — free account
Niki BioSolutions, Inc.
NIKI Healthcare Biotechnology
Niki BioSolutions, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $431,400.00, down 66.7% from fiscal 2022.
2.03
0.19
−8.56%
Follow NIKI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 2 | 3 | 4 | 6 | — | — | — |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 254.64 | 0.00 | 0.00 | — |
Altman Z-Score |
— | — | (5.03) | (6.50) | 1.25 | 5.94 | 25.90 | 19.77 | — |
P/S ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | — | (11.06) | (16.92) | (7.49) | 5.68 | (7.04) | 2.40 | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
— | — | (1.39) | (3.21) | (5.32) | — | — | — | — |
P/B ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Tangible BV |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Sales |
— | — | 0.55 | 0.49 | (3.37) | (20.27) | 0.00 | 0.00 | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.23 | 0.83 | 0.00 | 0.00 | — |
EV/Operating CF |
— | — | (0.04) | (0.03) | 0.19 | 0.63 | 0.00 | 0.00 | — |
EV/FCF |
— | — | (0.04) | (0.03) | 0.19 | 0.56 | 0.00 | 0.00 | — |
Quick Ratio |
0.78 | 0.22 | 1.18 | 0.56 | 2.87 | 8.65 | 2.87 | 2.29 | 15.11 |
Current Ratio |
0.78 | 0.22 | 1.18 | 0.57 | 2.90 | 8.70 | 3.00 | 2.36 | 15.24 |
Net Debt/EBITDA |
0.02 | (0.65) | (0.11) | (0.09) | 0.46 | 1.55 | 0.00 | 1.76 | 3.43 |
Debt/Assets |
18.29% | 20.08% | 14.82% | 31.21% | 1.04% | 6.07% | 27.20% | 22.74% | 1.52% |
Debt/Equity |
0.25 | 0.28 | 0.20 | 0.83 | 0.01 | 0.07 | 0.44 | 0.31 | 0.02 |
Asset Turnover |
0.00 | 0.00 | 0.02 | 0.06 | 0.05 | 0.03 | 0.02 | 0.01 | 0.00 |
Operating CF/Net income |
1.35 | 0.28 | 2.73 | 1.26 | 0.58 | (2.52) | 0.72 | 0.68 | 0.00 |
Capex/Depreciation |
— | 0.19 | 0.01 | (0.15) | (0.12) | 0.67 | (0.70) | (8.89) | 0.00 |
Interest Coverage |
(18.99) | (26.82) | (88.56) | 119.43 | (205.21) | (83.23) | (4.92) | (2.32) | — |
| (10.68%) | (31.43%) | (24.33%) | (77.35%) | (90.01%) | 23.81% | (78.52%) | (47.10%) | (8.04%) | |
| (7.83%) | (23.21%) | (13.61%) | (45.82%) | (75.75%) | 18.51% | (54.14%) | (38.71%) | (6.65%) | |
ROIC |
(8.29%) | (17.42%) | (40.78%) | (118.55%) | (129.97%) | (143.66%) | (76.81%) | (40.96%) | 0.00% |
Return on Tangible Assets |
136.15% | 126.29% | (138.38%) | 375.41% | (208.01%) | 18.31% | (150.08%) | (71.31%) | (13.20%) |
Average Days of Receivables |
0.00 | 0.00 | 398.25 | 541.94 | 965.41 | 577.11 | 764.17 | 605.32 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1,204.98% | 711.44% | 704.99% | 1,271.19% | 1,296.54% | 808.71% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 447.52% | 402.84% | 350.84% | 532.47% | 1,377.69% | 1,282.82% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.04 | 0.04 | 0.02 | 0.05 | 0.03 | 0.05 |
Share Based Compensation of Revenue |
— | — | 293.28% | 127.09% | 109.13% | 162.22% | 301.35% | 0.00% | — |
Graham Net Nets |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | (30.59%) | (19.53%) | (3.73%) | 0.39% | (4.04%) | (4.02%) | — |
Free Cash Flow Yield |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Revenue per Share |
0.00 | 0.00 | 0.95 | 3.63 | 4.40 | 2.93 | 1.84 | 1.37 | 0.00 |
Operating CF per Share |
(2.50) | (2.18) | (17.09) | (34.52) | (41.83) | (51.16) | (46.13) | (35.96) | 0.00 |
Capex per Share |
0.00 | 0.11 | 0.03 | (0.52) | (0.41) | 2.86 | (3.13) | (21.73) | 0.00 |
Free Cash Flow per Share |
(2.50) | (2.07) | (17.06) | (35.04) | (42.24) | (48.30) | (49.26) | (57.68) | 0.00 |
Cash per Share |
4.70 | 1.60 | 4.44 | 14.33 | 24.26 | 102.81 | 22.61 | 97.59 | 6.57 |
Shareholders Equity per Share |
18.70 | 21.60 | 34.03 | 21.95 | 49.97 | 122.52 | 51.20 | 117.33 | 10.04 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
18.70 | 21.60 | 34.03 | 21.95 | 49.97 | 122.52 | 51.20 | 117.33 | 10.04 |
Free Cash Flow |
(1.84) | (1.13) | (7.71) | (12.51) | (14.80) | (15.04) | (14.29) | (16.10) | 0.00 |
Working Capital |
(1.00) | (3.38) | 0.38 | (5.44) | 8.31 | 29.79 | 5.36 | 16.54 | 18.95 |
Capital Expenditures |
— | 0.06 | 0.01 | (0.19) | (0.14) | 0.89 | (0.91) | (6.06) | 0.00 |
Net Current Asset Value |
(1.35) | (3.39) | (2.78) | (5.97) | 8.29 | 27.58 | (1.07) | 16.39 | 18.95 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
— | 0.00 | (0.03) | 0.14 | 0.09 | (0.98) | 1.70 | 15.81 | 0.00 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.68 | 0.43 | 0.32 | 0.28 | 0.18 | 0.16 | 0.00 |
Cash ROIC |
(8.91%) | (7.12%) | (37.72%) | (64.26%) | (56.40%) | (20.65%) | (51.17%) | (22.92%) | 0.00% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.36 | 0.43 | 0.56 | 0.71 | 0.61 | 0.81 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.10 | 0.24 | 0.39 | 0.35 | 0.41 | 0.33 | 0.06 |
Inventory Turnover |
— | — | 0.00 | 38.29 | 38.98 | 27.69 | 24.52 | 9.81 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 1,643.11 | 1,851.36 | 1,043.22 | 1,165.41 | 1,188.26 | 1,431.42 | 4,048.46 |
Days of Inventory on Hand |
— | — | 0.00 | 8.32 | 8.95 | 14.06 | 15.71 | 35.12 | 0.00 |
Average Receivables |
0.11 | 0.28 | 1.20 | 3.00 | 2.76 | 1.28 | 0.88 | 0.47 | 0.59 |
Average Payables |
1.00 | 1.41 | 4.03 | 5.17 | 3.71 | 2.91 | 1.92 | 0.95 | 0.95 |
Average Inventory |
— | — | — | 0.03 | 0.04 | 0.04 | 0.03 | 0.03 | — |
Average Assets |
17.41 | 18.39 | 20.75 | 21.39 | 33.07 | 34.09 | 34.51 | 38.32 | 38.32 |
Average Common Equity |
12.76 | 13.58 | 11.61 | 12.67 | 27.83 | 26.50 | 23.80 | 31.49 | 31.68 |
Columns are period end dates · fundamentals updated 5 Oct 2026